Case Study

Tasly Pharmaceutical Group Co., Ltd.

4 pages
November 2015
Reference: IMD-7-1669

A pioneer in the modernization of traditional Chinese medicine, the publicly traded Tasly Pharmaceutical Group Co., Ltd. was founded in 1994 by Yan Xijun and his wife Wu Naifeng in Tianjin, China. The couple who met while training as pharmacists at a military medical school, had developed a new method to extract the active substance from Danshen, or red sage root, an herbal ingredient known to be effective in treating heart diseases. The active substance presented as “dripping pills” became the main product of Tasly, capturing 36% market share of this proprietary Chinese medecine. In 2005, the couple’s son Kaijing joined the company and in 2014 took over from his father Xijun as chairman of Tasly. Xijun had planned and executed his succession with military precision, ensuring that a professional management team was put in place to head the group while he and his wife, the first generation, took their leave as planned.

Learning Objective

This case sets the scene for a discussion on succession planning and governance in a publicly traded family business.

Succession Planning, Family Ownership, Non-family Chief Executive Officer, Non-family Member, Public Company, Management Role
Asia, China
Tasly Pharmaceutical, Healthcare, Pharmaceuticals
Published Sources
© 2015
Available Languages
Case clearing houses

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics